One Blood Draw. Fifty Cancers. The $689 Bet on Finding Them Early.

Performance data from development studies paint an honest picture. The test's specificity sits at 97.4%, meaning that out of every 100 people without cancer, roughly 97 will correctly get a clean result. That's important because false positives in cancer screening are terrifying; nobody wants a phone call saying "we found something" when nothing is there.

On the sensitivity side (how well it catches real cancers), the results are more nuanced. Overall sensitivity runs around 64% when you exclude breast and prostate cancers. For the six deadliest cancers on its list, sensitivity climbs to roughly 68%.

But here's where it gets complicated. Early-stage detection, the whole reason you'd want a screening test, is harder. The test catches about 39% of stage I and II cancers. By stage III and IV, sensitivity jumps to 82% and 90%, respectively. That makes intuitive sense: bigger tumors shed more DNA and proteins into the bloodstream, like a louder alarm that's easier to hear.

So Cancerguard is better at finding advanced cancers than early ones. That's not ideal for a screening test, but catching even a third of early-stage cancers that would otherwise go undetected until stage IV could still save lives. The question is whether the data will eventually prove that.

The Price Tag (and Who's Paying)

Cancerguard costs $689 per test, paid out of pocket. Insurance doesn't cover it, and neither does Medicare. You can use your HSA or FSA, and Exact Sciences offers payment plans, but this is fundamentally a cash-pay product right now.

If your result comes back positive, follow-up imaging (CT scans, PET scans) adds more cost. Exact Sciences offers up to $6,000 in reimbursement for certain non-covered imaging through a financial assistance program, though eligibility isn't guaranteed.

On the regulatory front, federal legislation passed in early 2026 creates a pathway toward Medicare coverage for MCED tests. But "pathway" is doing a lot of heavy lifting in that sentence. Actual Medicare reimbursement requires FDA approval first, and Cancerguard doesn't have that yet. It's sold as a laboratory-developed test (LDT) under CLIA regulations, which is the diagnostic industry's version of "technically legal but not formally blessed."

The Competition Is Heating Up

Exact Sciences isn't the only company chasing this market. Grail's Galleri test is the current front-runner in the MCED space, with the broadest real-world deployment and the most clinical data from studies like PATHFINDER and CCGA. Galleri also covers 50-plus cancer types and boasts specificity in the 99.5% to 99.6% range.

Guardant Health has its Shield test, which is FDA-approved for colorectal cancer screening specifically. Its multi-cancer version (Shield MCD) has Breakthrough Device designation from the FDA but remains in clinical trials. It's competition-in-waiting, not competition-on-shelves.

So the real 2026 MCED showdown is Cancerguard vs. Galleri. No head-to-head trial exists comparing them in the same patient population, which means any comparison is indirect. Cancerguard's multi-biomarker approach (DNA plus proteins) could theoretically offer advantages for certain cancer types, but that hypothesis needs rigorous validation.

The Elephant in the Room

No MCED test, not Cancerguard, not Galleri, not anything in development, has proven in a randomized controlled trial that it actually reduces cancer deaths. That's the billion-dollar question hanging over this entire category.

Detecting cancer earlier sounds like it should automatically save lives. But cancer screening is full of paradoxes. Overdiagnosis (finding cancers that would never have caused harm) can lead to unnecessary surgeries, chemotherapy, and anxiety. False positives trigger cascades of imaging and biopsies. In one large Galleri study, the positive predictive value was about 38%, meaning roughly 3 out of 5 people who got a "cancer signal detected" result turned out not to have cancer.

The American Cancer Society is clear on this: MCED tests do not replace standard screening. You still need your colonoscopy, your mammogram, your lung CT if you qualify. These blood tests are meant to be an additional layer of surveillance, not a shortcut.

Oncodetect: The Other Half of the Story

While Cancerguard grabs the headlines, Oncodetect quietly addresses a different (and arguably just as important) problem: monitoring for cancer recurrence after treatment.

The next-generation version, powered by technology called MAESTRO and slated for 2026, can track up to 5,000 patient-specific genetic variants. If Cancerguard is the smoke detector, Oncodetect is the carbon monoxide monitor: always on, watching for invisible danger.

So, Should You Care?

The honest answer: yes, but with realistic expectations. Cancerguard represents a genuine technological achievement, and the idea that a single blood draw could screen for dozens of cancers that currently have no screening test is legitimately exciting. For cancers like pancreatic and ovarian, where early detection is almost nonexistent, even modest sensitivity could shift the needle.

But we're still in the early innings. The test isn't FDA-approved. Insurance won't pay for it. The mortality benefit is unproven. And the 39% early-stage sensitivity means it will miss more early cancers than it catches.

Exact Sciences is running a 25,000-person registry study called FALCON to generate the real-world evidence needed for an FDA submission. That data will determine whether Cancerguard becomes part of standard medical practice or remains an expensive add-on for the worried well.

The race to make cancer screening as simple as a blood draw is on. We're just not at the finish line yet.

The Underdog That Just Knocked Out a $13 Billion Giant

UCB's Bimzelx just beat AbbVie's Skyrizi in a head-to-head psoriatic arthritis trial, posting the first-ever biologic superiority win on a major joint endpoint. The results could reshape how doctors pick treatments in a $13 billion market.